Literature DB >> 23211535

Comparison of two classifications of metabolic syndrome in the pediatric population and the impact of cholesterol.

F Prodam1, R Ricotti, G Genoni, S Parlamento, A Petri, C Balossini, S Savastio, G Bona, S Bellone.   

Abstract

BACKGROUND: To establish the rate of agreement in predicting metabolic syndrome (MS) in different pediatric classifications using percentiles or fixed cut-offs, as well as exploring the influence of cholesterol. SUBJECTS AND METHODS: Cross-sectional study in a tertiary care center. Nine hundred and twenty-three obese children and adolescents were evaluated for metabolic characteristics, cholesterol levels, the agreement rate and prevalence of MS across age subgroups with pediatric National Cholesterol Education Program/ Adult Treatment Panel III (NCEP-ATP III) and International Diabetes Federation (IDF) classifications.
RESULTS: The overall prevalence of MS was 36.2% and 56.7% with NCEPATP III and IDF. The overall concordance was fair (k: 0.269), with substantial values observed only in children older than 10 (k: 0.708) and 16 yr (0.694). Concordant subjects for both classifications, ≤6 yr, had higher triglycerides, blood pressure (p<0.05) and lower HDL-cholesterol (p<0.0001), with respect to those found to be discordant. Concordant subjects ranging 6-10 yr had all parameters higher than those discordant for IDF (p<0.01) and insulin resistance (p<0.05) than those discordant for NCEP-ATP III. Concordant subjects ≥10 yr presented more altered parameters than those included only in NCEP-ATP III (p<0.05). Overt glucose alterations were uncommon (7.4%; confidence interval 95% 0.1-14.9%), although glucose was modestly higher in MS subjects (p<0.01). Total and LDL-cholesterol was lower in subjects with MS than in those without (p<0.05), and in concordant rather than discordant subjects (p<0.05).
CONCLUSIONS: Classifications of MS do not identify the same pediatric population. Subjects who satisfied any classification were the most compromised. Lipid alterations were precocious in the youngest. Obese youths with MS presented lower total and LDL-cholesterol.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23211535     DOI: 10.3275/8768

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

2.  Relation of immediate postnatal growth with obesity and related metabolic risk factors in adulthood: the northern Finland birth cohort 1966 study.

Authors:  Ioanna Tzoulaki; Ulla Sovio; Demetris Pillas; Anna-Liisa Hartikainen; Anneli Pouta; Jaana Laitinen; Tuija H Tammelin; Marjo-Riitta Jarvelin; Paul Elliott
Journal:  Am J Epidemiol       Date:  2010-04-01       Impact factor: 4.897

3.  Prevalence of the insulin resistance syndrome in obesity.

Authors:  R M Viner; T Y Segal; E Lichtarowicz-Krynska; P Hindmarsh
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

4.  Progression from normal glucose tolerance to type 2 diabetes in a young girl: longitudinal changes in insulin sensitivity and secretion assessed by the clamp technique and surrogate estimates.

Authors:  Rola Saad; Neslihan Gungor; Silva Arslanian
Journal:  Pediatr Diabetes       Date:  2005-06       Impact factor: 4.866

5.  Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism.

Authors:  Julia Steinberger; Stephen R Daniels; Robert H Eckel; Laura Hayman; Robert H Lustig; Brian McCrindle; Michele L Mietus-Snyder
Journal:  Circulation       Date:  2009-01-12       Impact factor: 29.690

6.  Risk factors for impaired glucose tolerance in obese children and adolescents.

Authors:  Michaela Kleber; Gideon de Sousa; Sophie Papcke; Thomas Reinehr
Journal:  World J Diabetes       Date:  2010-09-15

7.  Comparison of metabolic syndrome prevalence using eight different definitions: a critical approach.

Authors:  Thomas Reinehr; Gideon de Sousa; André Michael Toschke; Werner Andler
Journal:  Arch Dis Child       Date:  2007-02-14       Impact factor: 3.791

Review 8.  Lipid screening and cardiovascular health in childhood.

Authors:  Stephen R Daniels; Frank R Greer
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

Review 9.  Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.

Authors:  David Preiss; Naveed Sattar
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-03       Impact factor: 3.478

10.  Diet high in fat and sucrose induces rapid onset of obesity-related metabolic syndrome partly through rapid response of genes involved in lipogenesis, insulin signalling and inflammation in mice.

Authors:  Zhi-Hong Yang; Hiroko Miyahara; Jiro Takeo; Masashi Katayama
Journal:  Diabetol Metab Syndr       Date:  2012-07-04       Impact factor: 3.320

View more
  3 in total

1.  Remission of loss of control eating and changes in components of the metabolic syndrome.

Authors:  Lisa M Shank; Marian Tanofsky-Kraff; Rachel M Radin; Lauren B Shomaker; Denise E Wilfley; Jami F Young; Sheila Brady; Cara H Olsen; James C Reynolds; Jack A Yanovski
Journal:  Int J Eat Disord       Date:  2018-04-01       Impact factor: 4.861

Review 2.  Obesity and infection: two sides of one coin.

Authors:  Giulia Genoni; Flavia Prodam; Agostina Marolda; Enza Giglione; Irene Demarchi; Simonetta Bellone; Gianni Bona
Journal:  Eur J Pediatr       Date:  2013-10-22       Impact factor: 3.183

3.  High-normal estimated glomerular filtration rate and hyperuricemia positively correlate with metabolic impairment in pediatric obese patients.

Authors:  Roberta Ricotti; Giulia Genoni; Enza Giglione; Alice Monzani; Martina Nugnes; Sara Zanetta; Matteo Castagno; Agostina Marolda; Giorgio Bellomo; Gianni Bona; Simonetta Bellone; Flavia Prodam
Journal:  PLoS One       Date:  2018-03-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.